Skip to main content

Maria del Mar Riveiro Barciela

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Maria del Mar Riveiro Barciela

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Research lines

Hepatitis virals i immunitat

Resposta immune en pacients amb hepatitis crònica B (HBeAg negatius)

Marcadors serològics i virològics per monitoritzar la infecció crònica per VHB i VHD

Mecanismes d'interacció entre VHB i VHD

Estudis fenotípics in vitro en models de transfecció o infecció del VHB i VHD

Virus de la hepatitis E

Eliminació del virus de la hepatitis C en poblacions d' alta prevalença

Mecanismes fisiopatològics de la hepatitis autoimmune

Hepatitis immunomediadas per inhibidors de checkpoint oncològics


Serveis o tecnologies rellevants:


Estudi de les quasispècies dels virus VHB i VHD per seqüenciació massiva

IP: Maria Buti Ferret, Maria del Mar Riveiro Barciela

Projects

Malalties hepàtiques

IP: Joan Genescà Ferrer
Collaborators: Beatriz Minguez Rosique, Sergi Colomer Castell, Elena Vargas Accarino, Immaculada Raurell Saborit, Lluís Viladomiu Catà, Lluis Castells Fusté, Maria del Mar Riveiro Barciela, Malalties hepàtiques, Maria Buti Ferret, Montserrat Gomez Perez, Torrens Buscató, Maria Margarita, Judit Vico Romero, Josep Quer Sivila, Adriana Palom Agusti, Juan Manuel Pericàs Pulido, Maria Nieves Martell Pérez-Alcalde, Damir Garcia Cehic, Daniel Martinez Vazquez, Laura Puente Ramo, Isabel Campos Varela, María Bermúdez Ramos, Juan Ignacio Esteban Mur, Ester Palacio Gutierrez, Susana Anton Calvo, Monica Higuera Urbano, Meritxell Ventura Cots, Ares Aurora Villagrasa Vilella, Emma Bigas Alsina, Carolina Campos Martinez, Macarena Simon-Talero Horga, Jesus Manuel Rivera Esteban, David Tabernero Caellas, Mònica Pons Delgado, Marcella Salzano, Cesar Jimenez Hernandez
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 60000
Reference: 2021 SGR 00462
Duration: 01/01/2022 - 30/06/2025

D-Mongolia: screening and linkage-to-care for Hepatitis D in Mongolian nationals living in Spain - Modalitat hepatitis

IP: Maria Buti Ferret
Collaborators: Maria del Mar Riveiro Barciela
Funding agency: GILEAD SCIENCES SLU
Funding: 48763
Reference: GLD21_00139
Duration: 30/06/2022 - 30/06/2024

Impact of HLA haplotypes and HDV viremia in developing of clinical events and quality of life of patients with chronic hepatitis delta.

IP: Maria Buti Ferret
Collaborators: Maria Jose Herrero Mata, Ana Barreira Diaz, Maria del Mar Riveiro Barciela, Jordi Llaneras Artigues, Adriana Palom Agusti, Maria luisa Roade Tato
Funding agency: Instituto de Salud Carlos III
Funding: 117370
Reference: PI20/01692
Duration: 01/01/2021 - 30/06/2025

Simplification of screening and treatment of hepatitis C in immigrant population in Barcelona.

IP: Maria del Mar Riveiro Barciela
Collaborators: -
Funding agency: GILEAD SCIENCES SLU
Funding: 49494.28
Reference: GLD19-00080
Duration: 24/10/2019 - 23/07/2021

Related news

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

The research team used nanotechnology to deliver the drug directly to liver cells, which eliminated side effects without reducing effectiveness.

Related professionals

Maria Urpí Castany

Maria Urpí Castany

Research technician
Diagnostic nanotools (DINA)
Read more
Maria Roca Herrera

Maria Roca Herrera

Predoctoral researcher
Systemic Diseases
Read more
Alba Márquez Gallego

Alba Márquez Gallego

Research technician
Cardiovascular Diseases
Read more
Claudia Ana Burillo Vargas

Claudia Ana Burillo Vargas

Liver Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.